Opna Bio Announces 2024 ASH Presentation Highlighting Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

November 13, 2024

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accepted for poster presentations at the American Society of Hematology (ASH) annual meeting, taking place Dec 7-10, 2024 in San Diego. The presentations will highlight data from Opna’s lead clinical programs, OPN-2853 and OPN-6602.